Caricotamide/Tretazicar

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameCaricotamide/Tretazicar
Drug Alias NameTretazicar/CaricotamideTretazicar+CaricotamideCaricotamide+TretazicarProlarixEP-0152R +[6
ClassificationSmall molecules
Mechanisms of ActionDNA cross linking agents
TargetsDNA
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited Kingdom
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBtg Plc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Birmingham
Inactive CompaniesBtg International Inc
Active IndicationsProstatic Neoplasms
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A